Hybrid aza-steroid alkylators in the treatment of colon cancer

Cancer Letters

Volumn 243, Issue 2, 2006, Pages 202-210

  Trafalis, Dimitrios T P ^a,b  

^a METAXA CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Colon carcinoma; Homo aza steroids; Human cell lines; In vitro; In vivo; Lactam steroid alkylator

Indexed keywords

LACTANDRATE; LACTESTOXATE; STEROID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; COLORIMETRY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; XENOGRAFT;

ALKYLATING AGENTS; ANIMALS; AZASTEROIDS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; NITROGEN MUSTARD COMPOUNDS; SECOSTEROIDS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RODENTIA;

EID: 33749354945     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.034     Document Type: Article

References (51)

1. Camoutsis C., and Trafalis D.T.P. An overview on the antileukemic potential of d-homo-aza- and respective 17β-acetamido- steroidal alkylating esters. Invest. New Drugs 21 (2003) 47-54
2. Catsoulacos P., and Catsoulacos D. Conjugated systems of homo-aza-steroidal esters in cancer chemotherapy. Anticancer Res. 14 (1994) 2525-2528
3. Trafalis D.T.P., Camoutsis C., Dalezis P., Papageorgiou A., Kontos M., Karamanakos P., et al. Antitumour effect of A- and D-lactam androgen nitrogen mustards on non-small cell lung carcinoma. J. BUON 9 (2004) 75-82
4. Catsoulacos P., Politis D., and Wampler G.L. A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother. Pharmacol. 3 (1979) 67-70
5. Catsoulacos P., Camoutsis C., and Wampler G.L. Effect of a D5-homo-aza-steroidal ester in P388 and L1210 murine leukemias. Oncology 39 (1982) 59-60
6. Catsoulacos P. Activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam p-bis(2-chloroethyl)aminophenoxy acetate (NSC-294859) on experimental tumor and leukemia systems. Oncology 40 (1983) 290-292
7. Catsoulacos P., and Wampler G.L. Activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam(p-bis(2 -chloroethyl)amino)-phenylacetate (NSC-290205) in murine solid tumors. Oncology 39 (1982) 109-112
8. Catsoulacos P. Further studies on the anti-neoplastic activity of 3b-hydroxy-13a-amino-13,17-seco-5a-androstan-17-oic-13,17-lactam(p-bis(2 -chloroethyl)amino)-phenylacetate (NSC-290205). Cancer Lett. 22 (1984) 199-202
9. Wall M.E., Abernethy S.G., Carroll J.F.I., and Taylor D.J. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J. Med. Chem. 12 (1969) 810-818
10. Wampler G.L., and Catsoulacos P. Antileukemic effect of homo-aza-steroidal-ester of p-[bis(2-chloroethyl)amino]acetic acid. Cancer Treat. Rep. 61 (1977) 37-41
11. Catsoulacos P., and Boutis L. Aza-steroids. Beckmann rearrangement of 3β-acetoxy-5α-androstan-17-one oxime acetate with boron fluoride. Alkylting agents. Chim. Ther. 8 (1973) 215-217
12. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst. 82 (1990) 1107-1112
13. Goldin A., Venditti J.M., and Geran R. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review. Invest. New Drugs 3 (1985) 3-21
14. N.I.H., Principles of laboratory animal care, N.I.H. publication, 85 (1985) 23.
15. Boring C.C., Squires T.S., Tang T., and Montgomery S. Cancer statistics. CA Cancer J. Clin. 44 (1994) 7-26
16. Gatta G., Ciccolallo L., Capocaccia R., Coleman M.P., Hakulinen T., Møller H., et al. EUROCARE Working Group, Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur. J. Cancer 39 (2003) 2214-2222
17. E.S.M.O. Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann. Oncol. 16 Suppl. 1 (2005) i16-i17
18. Wilkes G.M. Therapeutic options in the management of colon cancer: 2005 update. J. Clin. Oncol. Nurs. 9 (2005) 31-44
19. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10 (2005) 250-261
20. Haller D.G. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Semin. Oncol. 31 6 Suppl. 14 (2004) 10-16
21. Kabara J.J., Holzschu D.L., and Catsoulacos P. Structure function activity of azasterols and nitrogen containing steroids. Lipids 11 (1976) 7555-7562
22. Ma D., Wamg G., Wang S., Kozikowski A.P., Lewin N.E., and Blumberg P.M. Synthesis and protein kinase C binding activity of benzolactam-V-7. Bioorg. Med. Chem. Lett. 9 (1999) 1371-1374
23. Endo Y., and Yokohama A. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg. Med. Chem. Lett. 10 (2000) 63-66
24. Endo Y., Shimazu M., Fukasawa H., Driedger P.E., Kimura K., Tomioka N., et al. Synthesis, computer modeling and biological evaluation of novel protein kinase C agonists based on a 7-membered lactam moiety. Bioorg. Med. Chem. Lett. 9 (1999) 173-178
25. Catsoulacos P., Politis D., and Wampler G.L. Antitumor activity of homo-aza-steroidal esters of [p-bis(2-chloroethyl)amino]phenyl acetic acid and [p-bis(2-chloroethyl)amino]phenyl butyric acid. Cancer Chemother. Pharmacol. 10 (1983) 129-132
26. Catsoulacos P., and Catsoulacos D. Antitumor activity of homo-aza-steroidal esters of p-N,N-bis(2-chloroethyl)amino phenoxy acetic acid. Anticancer Res. 13 (1993) 1203-1208
27. Catsoulacos P., Camoutsis C., Papageorgiou A., and Adamiak-Margariti E. Cytostatic effect of homo-aza-steroidal esters in vivo and in vitro: structure-activity relationships. Anticancer Res. 12 (1992) 1617-1620
28. Dalmases P., Gomez-Belinchon J.I., Bonet J.-J., Giner-Sorolla A., and Schmid F.A. Antineoplastic agents. II. A nitrogen mustard derivative of N-methylated steroidal lactam. Eur. J. Med. Chem. 18 (1983) 541-543
29. Dalmases P., Cervantes G., Quintana J., and Bonet J.-J. Antineoplastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams. Eur. J. Med. Chem. 19 (1984) 465-467
30. Papageorgiou A., Ivanov I.G., Markov G.G., Koliais S.I., Boutis L., and Catsoulacos P. Interaction of homo-aza-steroidal ester of p-[bis-(2-chloroethyl)amino] acetic acid (ASE) with DNA of Ehrlich ascites tumor cells. FEBS Lett. 153 (1983) 194-198
31. Shepherd R.E., Huff K., and McGuire W.L. Brief communication: estrogen receptor interaction with antitumor agent estradiol mustard. J. Natl. Cancer Inst. 53 (1974) 895-897
32. Catsoulacos P., and Catsoulacos D. Conjugated systems of homo-aza-steroidal esters in cancer chemotherapy. Anticancer Res. 14 (1994) 2525-2528
33. Catsoulacos P., and Catsoulacos D. Hybrid anticancer compounds. Steroidal lactam esters of carboxylic derivative of N,N-bis(2-chloroethyl)aniline. Anticancer Res. 11 (1991) 1773-1778
34. Aviram R., Deutsch A., Patya M., Nordenberg J., Mor C., Reiss R., et al. Biochemical tissue markers of human colorectal carcinoma. Dis. Colon Rectum 31 (1988) 176-180
35. Lorenzi M., Vindigni C., Minacci C., Tripodi S.A., Iroatulam A., Petrioli R., et al. Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer. Int. J. Biol. Markers 12 (1997) 68-74
36. Wagner H.E., Toth C.A., Steele Jr. G.D., and Thomas P. Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production. Clin. Exp. Metastasis 10 (1992) 25-31
37. Goldin A., and Venditti J.M. Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute. Cancer Treat. Rev. 7 (1980) 167-176
38. Opolski A., Laskowska A., Madej J., Wietrzyk J., Klopocki A., Radzikowski C., et al. Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl antigen. Clin. Exp. Metastasis 16 (1998) 673-681
39. Jessup J.M., Petrick A.T., Toth C.A., Ford R., Meterissian S., O'Hara C.J., et al. Carcinoembryonic antigen: enhancement of liver colonization through retention of human colorectal carcinoma cells. Br. J. Cancer 67 (1993) 464-470
40. D.T.P. Trafalis, G.D. Geromichalos, C. Koukoulitsa, A. Papageorgiou, P. Karamanakos, C. Camoutsis, Lactandrate: A d-homo-aza-androsterone alkylator in the treatment of breast cancer, Breast Cancer Res. Treat. (in press) (published online: 01/12/2005).
41. Pispirigos K., Catsoulakos P., and Karakiulakis G. Evaluation of kidney and liver subacute toxicity of antitumor agents using serum biochemical parameters in rats. Biochem. Mol. Biol. Int. 31 (1993) 565-573
42. Pispirigos K., Paradelis A.G., and Karakiulakis G. Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo-aza-steroid ester with antitumor activity in rats using serum biochemical parameters. Arzneimittelforschung 47 (1997) 92-96
43. Kubota T., Kawamura E., Suzuki T., Yamada T., Toyoda H., Miyagawa T., et al. Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice. Jpn. J. Clin. Oncol. 16 (1986) 357-364
44. Stathopoulos G.P., Stergiou G.S., Golematis B., Thalassinos N., and Fillipakis M. Effect of adriamycin, 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer. Oncology 52 (1995) 306-309
45. Colucci G., Maiello E., Gebbia V., Giuliani F., Serravezza G., Lelli G., et al. 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group. Cancer 85 (1999) 535-545
46. Nanni O., Volpi A., Frassineti G.L., De Paola F., Granato A.M., Dubini A., et al. Role of biological markers in the clinical outcome of colon cancer. Br. J. Cancer 87 (2002) 868-875
47. Karr J.P., Wajsman Z., Kirdani R.Y., Murphy G.P., and Sandberg A.A. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J. Urol. 124 (1980) 232-236
48. Levell M.J., Siddall J.K., Rowe E., Glashan R.W., Robinson M.R., and Pidcock N.B. Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens. Prostate 11 (1987) 17-21
49. Qiu Y., Langman M.J., and Eggo M.C. Targets of 17 beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy?. J. Endocrinol. 181 (2004) 327-337
50. Izbicki J.R., Wambach G., Hamilton S.R., Harnisch E., Hogenschurz R., Izbicki W., et al. Androgen receptors in experimentally induced colon carcinogenesis. J. Cancer Res. Clin. Oncol. 112 (1986) 39-46
51. Catalano M.G., Pfeffer U., Raineri M., Ferro P., Curto A., Capuzzi P., et al. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int. J. Cancer 86 (2000) 325-330